Zacks Research Has Bullish Forecast for RDY Q2 Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a note issued to investors on Wednesday, October 16th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.00 for the quarter, up from their previous forecast of $0.99. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $4.11 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q3 2026 earnings at $1.01 EPS and FY2026 earnings at $4.07 EPS.

Separately, Barclays boosted their target price on shares of Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Stock Up 0.8 %

Shares of RDY stock opened at $79.80 on Thursday. Dr. Reddy’s Laboratories has a 12 month low of $63.72 and a 12 month high of $84.46. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. The firm has a market cap of $13.32 billion, a PE ratio of 19.80, a price-to-earnings-growth ratio of 1.73 and a beta of 0.55. The stock has a 50 day moving average of $80.46 and a 200-day moving average of $76.31.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Saturday, July 27th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.10 by ($0.10). The business had revenue of $919.80 million during the quarter, compared to analyst estimates of $861.68 million. Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%.

Institutional Trading of Dr. Reddy’s Laboratories

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its position in Dr. Reddy’s Laboratories by 3.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,995,495 shares of the company’s stock valued at $152,037,000 after purchasing an additional 65,606 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Dr. Reddy’s Laboratories by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock worth $76,455,000 after buying an additional 114,294 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in Dr. Reddy’s Laboratories by 318.0% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock worth $28,411,000 after acquiring an additional 283,700 shares during the last quarter. Millennium Management LLC increased its position in Dr. Reddy’s Laboratories by 61.4% in the 2nd quarter. Millennium Management LLC now owns 332,502 shares of the company’s stock valued at $25,333,000 after acquiring an additional 126,472 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Dr. Reddy’s Laboratories by 37.2% in the second quarter. Acadian Asset Management LLC now owns 269,131 shares of the company’s stock worth $20,500,000 after acquiring an additional 72,978 shares during the last quarter. Institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.